Weekly Analysts’ Ratings Changes for Keros Therapeutics (KROS)

Several brokerages have updated their recommendations and price targets on shares of Keros Therapeutics (NASDAQ: KROS) in the last few weeks:

• 8/27/2026 – Keros Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/24/2026 – Keros Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 8/16/2026 – Keros Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 8/12/2026 – Keros Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 8/8/2026 – Keros Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 8/4/2026 – Keros Therapeutics had its price target lowered by Wells Fargo & Company from $20.00 to $18.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Keros Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
• 8/4/2026 – Keros Therapeutics had its price target lowered by Leerink Partners from $30.00 to $23.00. They now have an “outperform” rating on the stock.
• 7/29/2026 – Keros Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.

Insider Transactions at Keros Therapeutics

In related news, Director Julius Knowles sold 2,625 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the transaction, the director directly owned 10,958 shares in the company, valued at approximately $117,579.34. This trade represents a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of Keros Therapeutics stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the sale, the director directly owned 9,767 shares in the company, valued at approximately $104,799.91. This represents a 21.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,768 shares of company stock valued at $144,979 over the last three months. 12.60% of the stock is currently owned by corporate insiders.

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.